Osteoporosis results from an imbalance in skeletal remodeling that favors bone resorption over bone formation. Bone matrix is degraded by osteoclasts, which differentiate from myeloid precursors in response to the cytokine RANKL. To gain insight into the transcriptional regulation of bone resorption during growth and disease, we generated a conditional knockout of the transcription factor nuclear factor of activated T cells c1 (Nfatc1). Deletion of Nfatc1 in young mice resulted in osteopetrosis and inhibition of osteoclastogenesis in vivo and in vitro. Transcriptional profiling revealed NFATc1 as a master regulator of the osteoclast transcriptome, promoting the expression of numerous genes needed for bone resorption. In addition, NFATc1 directly repressed osteoclast progenitor expression of osteoprotegerin, a decoy receptor for RANKL previously thought to be an osteoblast-derived inhibitor of bone resorption. "Cherubism mice", which carry a gain-of-function mutation in SH3-domain binding protein 2 (Sh3bp2), develop osteoporosis and widespread inflammation dependent on the proinflammatory cytokine, TNF-α. Interestingly, deletion of Nfatc1 protected cherubism mice from systemic bone loss but did not inhibit inflammation. Taken together, our study demonstrates that NFATc1 is required for remodeling of the growing and adult skeleton and suggests that NFATc1 may be an effective therapeutic target for osteoporosis associated with inflammatory states.
Introduction
Osteoporosis, the most common pathologic condition resulting from excessive bone destruction, afflicts 10 million Americans over the age of 50 and results in 1.5 million fractures annually (1, 2) . Congenital and acquired inflammatory conditions, such as cherubism and RA, cause regional bone loss leading to skeletal deformities (3, 4) . A scarcity of molecular targets in bone hinders the development of therapeutics for these diseases. Moreover, an inducible genetic system to terminate bone resorption in mice would facilitate the analysis of preclinical models of bone loss.
Osteoclasts are multinucleated, bone resorbing cells that differentiate from myeloid precursors in response to M-CSF and RANKL. Mice deficient in Csf1 (M-CSF), Tnfsf11 (RANKL), or either of their receptors (Csf1r [c-FMS] or Tnfrsf11a [RANK] ), have increased bone density (osteopetrosis) with an absence of osteoclasts (5, 6) . A decoy receptor for RANKL, TNFRSF11B (also known as osteoprotegerin [OPG] ), balances osteoclastogenesis in vivo (7, 8) . Although multiple tissues express OPG, most research has focused on osteoblasts as the physiologic source of OPG in the skeletal system (9) .
Nuclear factor of activated T cell (NFAT) proteins are a family of 5 inducible transcription factors (NFATc1-4 and NFAT5) that control numerous cellular differentiation processes, including immune cell activation, heart valve formation, and the growth of cartilage and stem cells (10) (11) (12) . NFATc1 is a target of RANK signaling. During osteoclastogenesis, NFATc1 expression is induced and this transcription factor can be identified at the promoters of osteoclast specific genes (13) (14) (15) (16) (17) (18) (19) . Studies interrogating NFATc1 in the skeletal system have been limited since Nfatc1-deficient mice die at E13.5 of cardiac valve defects (20, 21) . The importance of NFATc1 in osteoclastogenesis in vivo was confirmed through fetal liver complementation experiments (22) and by rescuing embryonic lethality by targeting expression of NFATc1 to the developing heart (23) . However, a tractable system to explore the role of NFATc1-mediated osteoclastogenesis in pathologic bone destruction was lacking. Moreover, a source of NFATc1-deficient osteoclast progenitors was not available, hindering discovery of the universe of NFATc1-regulated genes.
Cherubism is a rare, autosomal dominant, pediatric disorder characterized by fibroinflammatory infiltrates in the face, leading to disfiguring swelling and cystic changes in the jaw. Large numbers of multinucleated giant cells that express osteoclast markers are found within the lesion (24) . Mutations leading to cherubism were mapped to a signaling adapter molecule, SH3-domain binding protein 2 (SH3BP2) (25, 26) , which may promote NFAT activation (27) .
Recently, a mouse model of cherubism was developed (3) . These knock-in (KI) mice contain a missense mutation in Sh3bp2, resulting in a proline to arginine substitution (P416R), the most commonly identified mutation in cherubism (P418R in humans). Homozygous KI/KI mice exhibit multiorgan inflammation and severe systemic bone loss that is dependent on TNF-α derived from myeloid cells. In mouse models and humans, TNF-α has been implicated in the systemic bone loss associated with inflammatory conditions like RA and postmenopausal estrogen withdrawal states (28) . Mutant SH3BP2 enhances TNF-α production in macrophages and promotes osteoclastogenesis via ERK and spleen tyrosine kinase pathways, respectively (3). Since NFATs can promote both osteoclastogenesis (22) and TNF-α production (29, 30 ), here we have asked which aspects of the cherubism phenotype depend on NFATc1?
Using a conditional knockout strategy, we show that genetic ablation of Nfatc1 results in osteoclast-poor osteopetrosis. This result complements previous studies (22, 23) and extends the requirement of NFATc1 to bone remodeling in the growing and adult skeleton. Molecular profiling of highly purified osteoclast precursors reveals 2 families of NFATc1-regulated genes in osteoclasts: those that are augmented by NFATc1 and those that absolutely depend on this transcription factor. Remarkably, in the absence of NFATc1, RANKL stimulates the expression of OPG, identifying a previously unrecognized function for NFATc1 in this pathway. Last, we show that NFATc1 functions downstream of mutant SH3BP2 and prevents the enhanced osteoclastogenesis and systemic bone loss characteristic of "cherubism mice", which carry a gain-of-function mutation in Sh3bp2 (3). Notably, cherubism mice deficient in NFATc1 still display multiorgan inflammation. Thus, NFATc1 uncouples systemic inflammation from osteopenia in this unique model and may represent a therapeutic target for TNF-α-dependent bone loss.
Results
Creation of an Nfatc1 conditional knockout mouse. To circumvent embryonic lethality (20) , the exon encoding the regulatory domain of Nfatc1 (exon 3) was flanked with loxP sites (Nfatc1 fl/fl ) ( Figure 1A ) (31) . Nfatc1-deficient mice (Nfatc1 Δ/Δ ) were generated by crossing Nfatc1 fl/fl mice with a transgenic line expressing the Cre recombinase from a type I interferon inducible promoter (Mx1-Cre) (32) . Activation of Mx1-Cre by i.p. injection of polyinosinic-polycytidylic acid (poly I:C) resulted in complete deletion of exon 3 in BM DNA ( Figure 1B) , a greater than 95% reduction in Nfatc1 mRNA levels in BM ( Figure 1D ), and markedly diminished NFATc1 protein levels in splenic lysates ( Figure 1E ). Nfatc1 Δ/Δ mice develop osteoclast-poor osteopetrosis. Nfatc1 was ablated in 10-day-old pups to examine its role in the skeleton of growing and adult mice. Compared with littermate controls, Nfatc1 Δ/Δ mice displayed (a) short, club-shaped long bones, with higher radiodensity at the distal femur and proximal tibia (Figure 2 , A-C, and Supplemental Figure 1A ; supplemental material available online with this article; doi:10.1172/JCI35711DS1); (b) a massive increase in Von Kossa and toluidine blue-positive matrix (calcified cartilage) adjacent to the growth plates ( Figure 2 , D and E); and (c) growth plate dysplasia, characterized by an increase in thickness, acellular areas, and the retention of hypertrophic chondrocytes beyond the chondro-osseous junction ( Figure 2 , E and F). Other skeletal sites, such as diaphyseal cortical bone and the epiphysis did not display increased bone density (Supplemental Figure 1B and A.O. Aliprantis, data not shown). Some Nfatc1 Δ/Δ mice developed upper incisor overgrowth with short or absent lower incisors ( Figure 2G ). Lateral radiographs of the skull did not show impaction of the lower incisors in the jaw but did reveal widened, hyperdense mandibular condyles ( Figure 2H) . Histologically, the mandibular condyles of Nfatc1 fl/fl mice showed a thin cap of articular cartilage overlying a mature neck of compact bone, while those from Nfatc1 Δ/Δ mice displayed marked retention of hypertrophic cartilage ( Figure 2I ). These data suggest that the tooth phenotype observed in Nfatc1 Δ/Δ mice is a consequence of malocclusion from abnormal biomechanical properties at the mandibular condyle, though a selective defect in lower incisor growth cannot be excluded. The increased bone density in Nfatc1 Δ/Δ mice is not due to augmented osteoblast function because (a) these mice showed a trend toward reduced osteoblast numbers (Supplemental Figure  1 , C and D) and (b) Nfatc1 fl/fl mice expressing the Cre recombinase from the osteoblast-specific osterix promoter (33) did not display a similar high bone mass phenotype (Supplemental Figure 1E ). Taken together, Nfatc1 Δ/Δ mice display features of severe osteopetrosis, with improperly shaped long bones and a failure to resorb primary spongiosa (calcified cartilage), resulting in aberrant endochondral growth and ossification (34, 35) .
Osteopetrosis results from either a decrease in osteoclast numbers or a reduction in osteoclast function (6) . Therefore osteoclast differentiation was investigated in Nfatc1 Figure 3F ). To establish that the differentiation defect was due to a failure of osteoclast progenitors to differentiate, and not to a lack of progenitors, osteoclast precursors were purified. Within the CD11b lo/-CD3e -B220 -c-fms + population in BM are c-kit + and c-kit -cells, with the former being the most highly osteoclastogenic (36) . Similar numbers of each population were found in Nfatc1 fl/fl and Nfatc1 Δ/Δ BM ( Figure 3 , G and H). Fluorescence-activated cell sorting-purified (FACS-purified) BM-derived CD11b lo/-CD3e -B220 -c-kit + c-fms + osteoclast precursors (BMOcPs) from Nfatc1 Δ/Δ mice failed to generate osteoclasts ( Figure 3 , I and J). Importantly, M-CSF induced normal macrophage differentiation in Nfatc1 Δ/Δ BM cells, as determined by CD11b and F4/80 staining (A.O. Aliprantis, data not shown) (37) . In summary, Nfatc1-deficient mice display a progenitor intrinsic defect in osteoclastogenesis.
Nfatc1 deletion using lysozyme-M-Cre does not result in osteopetrosis. Lysozyme-M-Cre (LysM-Cre) (38) has been used to interrogate osteoclast function in mice carrying conditional alleles (39, 40) . LysM-Cre mice express the Cre recombinase from a myeloid specific promoter (38) . Surprisingly, no alterations in bone density or osteoclast differentiation were observed in Nfatc1 fl/Δ , LysM-Cre mice (Supplemental Figure 2 , A-C). This result was explained by the fact that LysM-Cre failed to efficiently delete the floxed allele in BM macrophage or osteoclast cultures (Supplemental Figure 2D) . However, near complete deletion was observed in peritoneal macrophages (Supplemental Figure 2E) . These findings are consistent with the original report of this line (38) and indicate that LysM-Cre may be of limited value to the study of conditional alleles in osteoclasts.
Microarray analysis of FACS-sorted osteoclast progenitors reveals 2 families of NFATc1-regulated genes in the developing osteoclast. NFATc1 is necessary for osteoclast differentiation in vivo and in vitro (Figures 2 and 3) (22) . However, the universe of NFATc1-regu- (6, 19) , were absolutely dependent on NFATc1 for expression ( Figure 4 , A and B). Likewise, Myo1d and Mst1r, potential regulators of bone resorption (41, 42) , depended on NFATc1. Lastly, Rcan2, a regulator of the NFAT pathway and homolog of Rcan1, an NFATc1 target gene in the heart (43), was only induced in NFATc1-sufficient cells. In contrast, the following genes, whose function in osteoclasts is established (35, 44, 45) , could be partially induced by RANKL even in the absence of NFATc1: Mmp9, Acp5, Ctsk, Car2, Mmp14, and Clcn7 ( Figure 4 , C and D). However, NFATc1 did augment the expression of all 6 genes. These data support NFATc1 as a broad regulator of osteoclast gene expression but suggest that NFATc1 is more essential to the control of some genetic loci than others.
Surprisingly, a microarray probe set (1417621_at) to Nfatc1 revealed expression in Nfatc1 Δ/Δ MROcPs ( Figure 4C ). This probe set targets the 3′ untranslated region of the Nfatc1/A isoform, which is preferentially induced during osteoclastogenesis and suggested to be a target of autoamplification (22) . Since neither fulllength Nfatc1 mRNA ( Figure 4E , primer set Nfatc1ex3, Table 1 ) nor NFATc1 protein could be detected in Nfatc1 Δ/Δ MROcPs (Supplemental Figure 3E ), this suggested that an untranslated, mutant Nfatc1/A mRNA is induced by RANKL in these cells. qRT-PCR confirmed the expression of Nfatc1/A mRNA in Nfatc1 Δ/Δ BMOcPs stimulated with RANKL ( Figure 4E) . Thus, the endogenous Table 1 Nfatc1 locus can still be stimulated by RANKL in the absence of NFATc1. However, NFATc1 was necessary for optimal expression, since higher levels of Nfatc1/A mRNA were detected in Nfatc1 fl/fl BMOcPs stimulated with RANKL compared with Nfatc1 Δ/Δ cells ( Figure 4E ), consistent with autoamplification (22) . Thus, Nfatc1/A is an NFATc1 augmented transcript. Since NFAT family members often display redundant functions (46) and NFATc2 is recruited to the Nfatc1 promoter (22) , the induction of Nfatc1/A mRNA by RANKL was investigated in NFATc2-deficient and NFATc1/NFATc2 doubly deficient BMOcPs. WT (Nfatc1 fl/fl Nfatc2 +/+ ) and NFATc2-deficient (Nfatc1 fl/fl Nfatc2 -/-) BMOcPs strongly upregulated Nfatc1/A in response to RANKL treatment for 4 days ( Figure 4F) . Interestingly, the induction of Nfatc1/A mRNA was not further attenuated in doubly deficient (Nfatc1 Δ/Δ Nfatc2 -/-) BMOcPs compared with those lacking NFATc1 alone (Nfatc1 Δ/Δ Nfatc2 +/+ ) ( Figure 4F ). These data suggest that NFATc2 does not play a dominant or compensatory role in the induction of Nfatc1/A mRNA during osteoclastogenesis.
Tnfrsf11b is upregulated in osteoclast precursors in the absence of NFATc1. Although the expression and function of OPG by osteoblasts has been well studied (47) , OPG expression by osteoclastlike cells has only been reported, to our knowledge, in giant cell tumors (24, 48) . Remarkably, 2 probe sets showed expression of Tnfrsf11b in Nfatc1 Δ/Δ MROcPs but not in Nfatc1 fl/fl cells ( Figure  5A ). In comparison, Tnfrsf11a expression levels were similar ( Figure  5A ). The expression of Tnfrsf11b mRNA by Nfatc1 Δ/Δ MROcPs was similar to levels found in WT osteoblasts ( Figure 5B ), increased over time in culture ( Figure 5C ), and was dependent on RANKL, as cells cultured in M-CSF alone did not express Tnfrsf11b (Figure 5D ). In addition, OPG was detected in the culture supernatants of Nfatc1 Δ/Δ MROcPs ( Figure 5E ). Treatment of Nfatc1 fl/fl MROcPs with cyclosporine A, an inhibitor of the NFAT activating phosphatase calcineurin (10), reciprocally upregulated Tnfrsf11b and downregulated the NFATc1-dependent gene, Itgb3 (Figure 5,  F and G) . Despite the dramatic upregulation of Tnfrsf11b mRNA by Nfatc1 Δ/Δ MROcPs, no differences in serum OPG levels were observed between Nfatc1 fl/fl and Nfatc1 Δ/Δ mice (Supplemental Figure 4) . To exclude the possibility that cells of mesenchymal origin (i.e., osteoblasts) were contaminating our BMOcP preparations from Nfatc1 Δ/Δ mice and producing the OPG signal observed in these experiments, osteoclast precursors were derived from spleen cells. Similar to FACSsorted BMOcPs, Nfatc1 Δ/Δ spleen cells both failed to differentiate into osteoclasts and upregulated Tnfrsf11b upon stimulation with RANKL (Supplemental Figure  5 , A-D). Interestingly, a putative NFAT binding site was identified in a conserved region of the human TNFRSF11B and mouse Tnfrsf11b promoters, located approximately 2 kb and 3 kb from the transcription start site (TSS), respectively (Supplemental Figure 6A) . After 3 days of RANKL treatment, NFATc1 was recruited to the Tnfrsf11b promoter, as determined by a ChIP assay using primers flanking this conserved sequence ( Figure 5H and Supplemental Figure 6A ). In contrast, NFATc1 binding to the Itgb3 promoter peaked at 1.5 days of RANKL treatment and was almost undetectable by 3 days (Supplemental Figure 6B) , consistent with previous observations (18) . Lastly, a constitutively active version of NFATc1 (caNFATc1) repressed the basal activity of a Tnfrsf11b reporter plasmid (pOPG 3.6-luc) ( Figure 5I ). Appropriately, caNFATc1 had little effect on an NF-κb reporter plasmid (pBII-luc) and strongly activated an NFAT luciferase reporter construct (pNFAT-luc) (Supplemental Figure  6 , C and D). Taken together, these results uncover a previously unrecognized regulatory loop downstream of RANKL: calcineurin/NFATc1-mediated repression of OPG expression.
NFATc1 dissociates systemic bone loss and osteoclastogenesis from inflammation in cherubism. Our conditional knockout strain represents a unique tool to evaluate the role of NFATc1 in disease. Cherubism is a pediatric, craniofacial, inflammatory disorder, characterized by bone loss in the jaw that is caused by mutations in an adapter molecule SH3BP2 (3, 25) . To clarify the role of NFATc1 in cherubism, Mx1-Cre was used to ablate Nfatc1 in mice carrying 1 (KI/+) or 2 (KI/KI) cherubism alleles (3). This approach was taken since the cherubism phenotype is intrinsic to myeloid cells (3) and deletion of Nfatc1 fl/fl by Mx1-Cre is complete in the BM (Figure 1, B and D) . Deletion of Nfatc1 reversed the diffuse bone loss and focal cystic changes characteristic of cherubism mice ( Figure 6A ). In contrast, Nfatc1 Δ/Δ KI/KI mice still developed widespread inflammation in the liver and lungs ( Figure 6 , B and C) as well as lymph nodes, spleen, and stomach (A.O. Aliprantis and Y. Ueki, data not shown). The systemic bone loss and inflammatory phenotypes of cherubism mice are dependent on TNF-α derived from myeloid cells, which express abnormally high levels of Tnf mRNA (3). Consistent with our observation that deletion of Nfatc1 had no effect on inflammation in vivo, BM macrophage cultures from KI/+ and KI/KI mice Table 1 qRT-PCR primers used in this study expressed higher levels of Tnf mRNA than WT cells irrespective of their Nfatc1 genotype ( Figure 6D ). Thus, NFATc1 uncouples diffuse osteopenia from inflammation in this TNF-α driven, clinically relevant mouse model of a human disease. Furthermore, the enhanced osteoclastogenesis conferred by mutant SH3BP2 in vitro, which occurs in a gene dosage-dependent manner, was completely abolished in BM cells lacking NFATc1, as assessed by TRAP staining ( Figure 7A ) or the expression of NFATc1-regulated genes ( Figure 7B Figure 7D ). Moreover, NFATc1 was not detected in Nfatc1 Δ/Δ cells, irrespective of their Sh3bp2 genotype (+/+ or KI/KI) or RANKL treatment ( Figure 7D ). These observations strongly suggest that SH3BP2 promotes osteoclastogenesis by augment- ing NFATc1 autoamplification. Since TNF-α has been reported to induce osteoclast differentiation independent of RANKL (49) and Sh3bp2 mutant mice have elevated levels of TNF-α (3), osteoclast differentiation was assessed in vivo in cherubism mice lacking NFATc1. Consistent with our observations of increased bone density in Nfatc1 Δ/Δ KI/KI mice ( Figure 6A ) and failure of BM cells from these mice to differentiate into osteoclasts in vitro ( Figure 7 , A and B), a dramatic reduction in TRAP-positive cells was seen at the proximal humerus ( Figure 7E ) and distal femur (A.O. Aliprantis and Y. Ueki, data not shown) of Nfatc1 Δ/Δ KI/KI compared with Nfatc1 fl/fl KI/KI mice. These data imply that TNF-α in this model cannot drive NFATc1-independent osteoclast differentiation.
Primer set Forward primers (5′-3′) Reverse primers (5′-3′)
Nfatc1ex3 A TGCCTTTTGCGAGCAGTATCT CAGGCAAGGATGGGCTCATAT Nfatc1/A B GGTAACTCTGTCTTTCTAACCTTAAGCTC GTGATGACCCCAGCATGCACCAGTCACAG Itgb3 C TCCAGACCCTGGGTACCAAG GCCAATCCGAAGGTTGCTAG Calcr C GCCTCCCCATTTACATCTGC CTCCTCGCCTTCGTTGTTG Myo1d A TCATTCGAACACCCCGTACAC CACGCCACACCTTTTGTAGGA Oscar A TCTGCCCCCTATGTGCTATCA AGGAGCCAGAACCTTCGAAAC Rcan2 A CCACTCTGGTCGCCTGTGT CGGAACAGTCCCTCGAATTTTTCCTTA Mst1r A TCACCACCAAGTCCGATGTGT AGGTCGAAGGGATCGATATGG Tnfrsf11b D (OPG) TGTCCAGATGGGTTCTTCTCA CGTTGTCATGTGTTGCATTTCC Mmp9 C ACGGACCCGAAGCGGAC GGGATACCCGTCTCCGTGC Acp5 C CAGCAGCCCAAAATGCCT TTTTGAGCCAGGACAGCTGA Ctsk C GGGCTCAAGGTTCTGCTGC TGGGTGTCCAGCATTTCCTC Car2 D TCCCACCACTGGGGATACAG CTCTTGGACGCAGCTTTATCATA Mmp14 D AGTGACAGGCAAGGCTGATTT AGGGGTGTAATTCTGAATGCAG Clcn7 D CGCCAGTCTCATTCTGCACT GCTTCTCGTTGTGTGGAATCT
Discussion
Evidence for the role of NFATc1 in osteoclastogenesis in vivo has been provided by 2 other studies. The first showed that Nfatc1-deficient fetal liver or embryonic stem cells do not rescue the osteopetrotic phenotype of c-fos -/-mice (22) . The second study targeted NFATc1 expression to the developing heart to rescue embryonic lethality. Nfatc1 -/-, Tie2-Nfatc1 mice showed osteopetrosis with absent osteoclasts (23) . These studies examined mice at 6 and 3 weeks, respectively, and provided important evidence for the function of NFATc1 in specifying osteoclast differentiation during development. However, the requirement for NFATc1 in adult skeletal remodeling remained unresolved. Here Mx1-Cre was used to delete Nfatc1 in mice at 10 days of age as was previously done to investigate the role of Iκβ kinase β in osteoclast survival (50) . Nfatc1 Δ/Δ mice developed osteoclast-poor osteopetrosis that was most prominent in the long bones and mandibles (Figures 2 and 3 ). Our data complement these previous studies (22, 23) and extend the requirement for NFATc1 to remodeling of the growing and adult skeleton. Moreover, unlike osteopetrotic, M-CSF-deficient op/op mice, which resolve their phenotype with age (51), Nfatc1 Δ/Δ mice up to the age of 5 months still displayed osteopetrosis. Interestingly, TRAP5b levels were reduced but not absent in Nfatc1 Δ/Δ mice ( Figure 3C ). This observation may be due to variability in Nfatc1 fl/fl deletion by Mx1-cre at anatomic sites not examined in the current study (e.g., the vertebral skeleton). In our experience, within the bone marrow of long bones, Mx1-cre-mediated deletion of Nfatc1 fl/fl was nearly complete at the level of DNA recombination or mRNA expression ( Figure 1, B and D) . NFATc1 binds the promoters of many osteoclast-specific genes, including Nfatc1 itself (13) (14) (15) (16) (17) (18) (19) 22) . However, a source of NFATc1-deficient osteoclast progenitors from mouse BM was not available prior to this study. Therefore, the relative contribution of NFATc1 to the expression of the osteoclast transcriptome could not be determined using loss of function experiments. To facilitate this analysis, a strategy to isolate a pure population of BMOcPs was devised (Supplemental Figure 3) . Transcriptional profiling revealed NFATc1 as a broad regulator of osteoclast gene expression (Figure 4) . Two sets of NFATc1-regulated genes were identified: those that are augmented by NFATc1 (Figure 4 , C and D) but still induced to some extent by RANKL in NFATc1-deficient cells and those that absolutely depend on NFATc1 for expression (Figure 4, A and B) . The temporal recruitment of NFATc1 to different genetic loci may underlie this observation. Recently, ChIP analyses have demonstrated that NFATc1 binds the Itgb3, Oscar, Acp5, and Ctsk promoters during osteoclastogenesis (16) (17) (18) 52) . Interestingly, whereas NFATc1 was recruited to the Itgb3 and Oscar promoters (NFATc1-dependent genes) within 12-48 hours of RANKL stimulation (17, 18, 52), NFATc1 was only detected at the Acp5 and Ctsk promoters (NFATc1-augmented genes) at day 5 after RANKL stimulation (16) . The fact that we see differences in expression of Acp5 and Ctsk at day 3 ( Figure 4D ) between NFATc1-sufficient and -deficient cells is likely due to our use of highly osteoclastogenic BMOcPs. We hypothesize that NFATc1-dependent genes need early NFATc1 recruitment to initiate transcription, whereas NFATc1-augmented genes employ NFATc1 at later time points to effect optimal expression. Other possible reasons these 2 sets of genes differentially require NFATc1 include compensatory use of other osteoclast transcription factors, like AP-1, c-Fos, Pu.1, and Mitf (19, 53) , and indirect effects of NFATc1 deficiency.
The most intriguing finding from our profiling experiments was the dramatic upregulation of Tnfrsf11b mRNA and protein by RANKL in NFATc1-deficient BMOcPs ( Figure 5 ). OPG, a decoy receptor for RANKL, is a potent negative regulator of osteoclastogenesis. Hence, OPG-deficient mice are osteoporotic (54) while OPG transgenic mice, like RANK knockout mice, display increased bone mass (7, 55) . Osteoblasts are thought to be the physiologic source of OPG in the skeleton (47) . However, contaminating osteoblasts are very unlikely to be the source of OPG in our experiments, since a pure population of BMOcPs, isolated by flow cytometry, was used. Moreover, osteoclast precursors derived from Nfatc1 Δ/Δ spleen cells also upregulated Tnfrsf11b mRNA in response to RANKL. Although, the physiologic significance of our observation is presently unknown, we suggest that NFATc1 dampens the induction of OPG that occurs as a consequence of signaling pathways shared by RANK and other TNF receptor family members. The RANKL/RANK/OPG axis has a well-described role outside of the skeleton in regulating adaptive immune responses (9) . In human B cells and dendritic cells, CD40 ligation induces OPG expression (56, 57) . CD40, like RANK, is a member of the TNF receptor superfamily. Both receptors utilize TNF receptor-associated factor 6 as a proximal signaling component (58, 59) . However, RANK is unique in its ability to promote calcium oscillations and upregulate NFATc1 (59) . Consistent with these observations, WT BMOcPs stimulated with RANKL in the presence of cyclosporine A, which blocks calcium-mediated activation of the calcineurin/ NFAT pathway, express more Tnfrsf11b mRNA ( Figure 5F ). Furthermore, it is likely that NFATc1 directly, negatively regulates the Tnfrsf11b promoter ( Figure 5 , H and I), which is similar to the observation in previous reports that NFAT family members repress Cdk4 expression (12, 60) . Taken together, these observations suggest that suppression of OPG expression downstream of RANKL is a previously unrecognized function of NFATc1 in osteoclastogenesis. Interestingly, giant cell tumors of bone, which contain multinucleated giant cells with features of osteoclasts, have been shown to express OPG (24, 48) . This intriguing clinical correlate suggests that dysregulation of OPG expression by cells of the osteoclast lineage may occur in pathologic conditions. Our Nfatc1 conditional knockout mouse provides a genetic system to study the role of this transcription factor in disease. Here, a mouse model of the human disorder, cherubism, was investigated. Cherubism mice carry a gain-of-function mutation in Sh3bp2 and develop systemic inflammation and bone loss due to overproduction of TNF-α by myeloid cells (3). NFATc1-deficient mice homozygous for the cherubism mutation still developed inflammation in multiple organs ( Figure 6 , B and C). In addition, macrophages grown from the BM of Nfatc1 Δ/Δ KI/KI mice had similarly elevated levels of Tnf transcripts compared with their NFATc1-sufficient counterparts ( Figure 6D ). These results indicate that NFATc1 is not downstream of SH3BP2 for TNF-α production and are consistent with a recent report that NFATc1 does not promote TNF-α expression in T cells (30) . However, the inflammatory phenotype of cherubism may depend on other NFAT family members, like NFATc2 (30, 61, 62) . Genetic ablation of Nfatc1 did protect cherubism mice from systemic bone loss ( Figure 6A ) and completely abrogated the enhanced osteoclastogenesis observed in vitro in BM cells carrying mutant alleles of Sh3bp2 ( Figure 7, A and  B) . Mutant Sh3bp2 cells also displayed increased induction of the Nfatc1/A isoform by RANKL in a manner proportional to gene dosage. This effect was not observed in NFATc1-deficient cells ( Figure 7C ). Taken together, these observations situate SH3BP2 upstream of NFATc1 in osteoclastogenesis, likely within the NFATc1 autoamplification loop. Cherubism mice also develop TNF-α-dependent arthritis with cortical erosions (3). Whether NFATc1 deficiency will protect from local bone loss around inflamed joints, as has been described for osteoclast-deficient mice in other arthritis models (63, 64) , is under investigation.
In conclusion, this study reveals that NFATc1 is an important regulator of osteoclastogenesis in growing and adult mice consistent with previous reports exploring its function in embryonic and early postnatal development (22, 23) . NFATc1 deficiency also protects from systemic bone loss in a mouse model of the human disease, cherubism, without inhibiting the inflammatory aspects of the disease. A gene profiling approach revealed that most genes classically associated with terminal osteoclast differentiation require NFATc1 for expression. Intriguingly, we found that RANKL promoted a dramatic induction of OPG in NFATc1-deficient cells. We propose that pharmacologic perturbation of the NFAT pathway in osteoclast precursors may transform these cells into potent OPG producers, which could inhibit resorption in the bone microenvironment and lead to novel treatments for osteolysis.
Methods
Creation of an Nfatc1 conditional knockout allele. A targeting vector containing exon 3 of Nfatc1 and a neomycin resistance cassette, both flanked by loxP sites, was generated ( Figure 1A ) using lambda phage murine Nfatc1 spleen cells incubated with M-CSF for 3 days. M-CSF (R&D Systems) and RANKL (RANKL/TRANCE was a kind gift from Y. Choi, University of Pennsylvania, Philadelphia, Pennsylvania, USA) were used at final concentrations of 20 ng/ml and 200-300 ng/ml, respectively. For the cherubism studies, M-CSF and RANKL were purchased from Peprotech and were used at the concentrations indicated in the figure legends. For coculture experiments, neonatal calvarial osteoblasts were purified from BALB/c mice as described (72) and plated at a density of 6,000 cells per well in 96-well plates. After an overnight incubation, 1 × 10 5 M-CSF-primed BM cells, 10 nM Vitamin D3 (Sigma-Aldrich), and 10 μM PGE2 (Calbiochem) were added. Biochemical assays for TRAP secreted into the culture supernatant (73) or staining of cellular TRAP (using either a commercially available kit [Sigma-Aldrich] or as previously described in ref. 69 ) were performed after 4 or 5 days (recombinant cytokines) or after 8 days (coculture). Where indicated, osteoblasts were treated for 2 hours with 10 nM Vitamin D3 (Sigma-Aldrich) and 10 nM parathyroid hormone (Sigma-Aldrich). To generate samples for Southern blot, peritoneal macrophages were collected 3-4 days after i.p. injection of 40 μg of Concanavalin A (Sigma-Aldrich) as described previously (74) .
DNA microarray analysis of MROcPs. Independently prepared duplicate samples containing pooled cells from multiple mice for each genotype were analyzed. Briefly, CD11b lo/-CD3e -B220 -c-kit + c-fms + BMOcPs from 8- to 13-week-old Nfatc1 Δ/Δ and Nfatc1 fl/fl littermate controls (n = 4/genotype, replicate 1 and n = 3/genotype, replicate 2; respectively) were incubated at an initial density of 20,000 per well in 24-well plates, with 1.2 ml αMEM-10 supplemented with M-CSF and RANKL. After 3 days of culture, mRNA was purified (RNeasy; Qiagen) and RNA profiling was performed by the microarray facility at the Harvard Medical School and Partners Center for Genetics and Genomics using the Affymetrix mouse 430A 2.0 array, which contains probes for approximately 14,000 well-characterized mouse genes. Data for all 4 samples were scaled to 500 and replicate samples were averaged for reporting in Figure 4 . A gene was classified as "NFATc1 augmented" if (a) the expression level of that gene was higher in Nfatc1 fl/fl samples compared with Nfatc1 Δ/Δ samples and (b) a "present" detection call was designated in both samples for the probe set recognizing that gene. "NFATc1 dependent" genes had an "absent" detection call for either one or both of the Nfatc1 Δ/Δ samples and were "present" at higher expression levels in Nfatc1 fl/fl samples. A similar experimental design was used to generate independent RNA samples for validation of the microarray results by qRT-PCR.
In silico analysis of the Tnfrsf11b promoter and NFATc1 ChIP assay. The mouse and human genomic sequences 3.6 kb upstream of the Tnfrsf11b gene were extracted from Ensembl database (www.ensembl.org). Z picture and rVista options in ECR browser (75) were used to identify and align regions of high conservation and putative NFATc1 binding sites in this region, respectively. ChIP assays were performed as described previously (16) . Briefly, WT M-CSF-primed spleen cells were incubated with RANKL and immunoprecipitation was carried out on precleared, sheared soluble chromatin with anti-NFATc1 (Santa Cruz Biotechnology Inc.) or nonspecific IgG overnight at 4°C. Immune complexes were isolated using Protein G agarose, washed, decrosslinked, and purified as described previously (16) . ChIP samples were analyzed by qRT-PCR for the Tnfrsf11b promoter using the FastStart TaqMan Master kit (Roche) and the universal probe library (Roche Diagnostics) with the following primers: 5′-TTAGGGAATACCT-CAGGAAAATACA-3′ (forward) and 5′-TTGTAGGAGCACGAGGTGAA-3′ (reverse). Analysis for the Itgb3 promoter was performed as described (18) . The signal for the promoter being studied was adjusted using input threshold values as a reference and is reported as relative enrichment.
Promoter luciferase assays. A firefly luciferase reporter plasmid containing 3.6 kb of the Tnfrsf11b proximal promoter (pOPG 3.6-luc) was a gift of G. Karsenty, Columbia University (76). An expression plasmid for constitutively active NFATc1 (pMSCV-caNfatc1) was a gift of N. Clipstone, Northwestern University, Chicago, Illinois, USA (77) . 293T cells were transiently transfected using the Effectene Reagent (Qiagen) with the indicated luciferase reporter plasmids and a Renilla luciferase vector (pRL-TK) as an internal control at a ratio of 10:1, along with the indicated amounts of pMSCV-caNfatc1. The total amount of DNA per transfection was held constant by supplementing with empty vector DNA. Forty hours after transfection Firefly and Renilla luciferase activities were determined in cell lysates using the Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activity was normalized to Renilla luciferase to control for transfection efficiency.
Immunofluorescence of NFATc1. BMOcPs were cultured on chamber slides for 3 days with M-CSF and RANKL. Cells were fixed with 4% PFA, permeabilized, and stained with anti-NFATc1 and goat anti-mouse Alexa Fluor 488 (Invitrogen). Hoechst (Sigma-Aldrich) was used as a nuclear counterstain.
Quantification of TRAP5b and OPG. Commercially available kits were used to determine the concentrations of TRAP5b (Immunodiagnostic Systems) in mouse serum or OPG (R&D Systems) in mouse serum or tissue culture supernatants according to the manufacturer's directions. Since RANKL in the tissue culture supernatants of osteoclast cultures can interfere with the OPG ELISA, supernatants were collected from BMOcPs first incubated for 4 days with M-CSF or M-CSF and RANKL and then cultured for 2 days with M-CSF only.
Statistics. Unpaired, 2-tailed Student's t tests were used for all statistical comparisons. A P value of less than 0.05 was considered significant.
